TY - JOUR
T1 - Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding β-catenin
AU - Lazar, Alexander J.F.
AU - Calonje, Eduardo
AU - Grayson, Wayne
AU - Dei Tos, Angelo P.
AU - Mihm, Martin C.
AU - Redston, Mark
AU - McKee, Phillip H.
PY - 2005/2
Y1 - 2005/2
N2 - Mutations in β-catenin are present in benign pilomatrixomas. β-catenin is a downstream effector in the WNT-signalling pathway, acting as a signal for differentiation and proliferation. Mutations in CTNNB1, the gene encoding β-catenin, are present in a wide variety of benign and malignant neoplasms. We examined β-catenin in a series of pilomatrix carcinomas (15 cases) by using immunohistochemistry and DNA sequencing of exon 3 from CTNNB1, and compared these to a series of benign pilomatrixomas (13 cases). All 11 pilomatrix carcinomas available for examination showed nuclear localization of β-catenin and mutations in exon 3 similar to those demonstrated in benign pilomatrixomas. Two of 11 pilomatrix carcinomas showed significant nuclear accumulation of p53, whereas this was absent in all 13 benign pilomatrixomas. Expression of nuclear cyclin D1 was similar in both benign pilomatrixomas and pilomatrix carcinomas. Clinical follow-up from the 15 malignant cases reported in this study and by others indicates that wide excision offers superior control of local recurrence, compared to simple excision. Immunohistochemical and molecular analysis of β-catenin reveals that both pilomatrix carcinomas and benign pilomatrixomas harbour mutations in β-catenin. This implies a common initial pathogenesis and is compatible with the proposition that pilomatrix carcinomas may at least on occasion arise from their benign counterparts.
AB - Mutations in β-catenin are present in benign pilomatrixomas. β-catenin is a downstream effector in the WNT-signalling pathway, acting as a signal for differentiation and proliferation. Mutations in CTNNB1, the gene encoding β-catenin, are present in a wide variety of benign and malignant neoplasms. We examined β-catenin in a series of pilomatrix carcinomas (15 cases) by using immunohistochemistry and DNA sequencing of exon 3 from CTNNB1, and compared these to a series of benign pilomatrixomas (13 cases). All 11 pilomatrix carcinomas available for examination showed nuclear localization of β-catenin and mutations in exon 3 similar to those demonstrated in benign pilomatrixomas. Two of 11 pilomatrix carcinomas showed significant nuclear accumulation of p53, whereas this was absent in all 13 benign pilomatrixomas. Expression of nuclear cyclin D1 was similar in both benign pilomatrixomas and pilomatrix carcinomas. Clinical follow-up from the 15 malignant cases reported in this study and by others indicates that wide excision offers superior control of local recurrence, compared to simple excision. Immunohistochemical and molecular analysis of β-catenin reveals that both pilomatrix carcinomas and benign pilomatrixomas harbour mutations in β-catenin. This implies a common initial pathogenesis and is compatible with the proposition that pilomatrix carcinomas may at least on occasion arise from their benign counterparts.
UR - http://www.scopus.com/inward/record.url?scp=13444269107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13444269107&partnerID=8YFLogxK
U2 - 10.1111/j.0303-6987.2005.00267.x
DO - 10.1111/j.0303-6987.2005.00267.x
M3 - Article
C2 - 15606674
AN - SCOPUS:13444269107
SN - 0303-6987
VL - 32
SP - 148
EP - 157
JO - Journal of cutaneous pathology
JF - Journal of cutaneous pathology
IS - 2
ER -